Clinical Trial

Effectiveness of Systane PRO for Mild to Moderate Dry Eye Disease

Study acronym: SYSTANEPRO1
Completed Phase 4
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to show that consistent use of Systane PRO over a 30 period will significantly improve the signs and symptoms of Dry Eye Disease and decrease patients' ocular surface disease index score for patients diagnosed with mild-moderate (DED).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-06-04.
Trial Details
NCT Number NCT07639034
Lead Sponsor Gordon Schanzlin New Vision
Conditions Dry Eye Disease (DED)
Enrollment 33 participants
Start Date 2025-11-01
Primary Completion 2026-02-01 (estimated)
Study Completion 2026-02-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-17